Angiodynamics (ANGO) Cash & Equivalents (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Cash & Equivalents data on file, last reported at $53.9 million in Q2 2026.

• Quarterly Cash & Equivalents fell 3.63% year-over-year to $53.9 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $53.9 million (down 3.63% YoY) and the FY2026 annual result came in at $53.9 million, down 3.63% from the prior year.
• Cash & Equivalents grew to $53.9 million in Q2 2026, from $37.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $78.5 million in Q1 2024 to a low of $23.9 million in Q1 2022.
• A 5-year average of $46.5 million and a median of $44.7 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 56.14% — and 2024, when it soared 160.54%.
• Tracing ANGO's Cash & Equivalents over 5 years: stood at $29.9 million in 2022, then soared by 103.96% to $60.9 million in 2023, then fell by 11.18% to $54.1 million in 2024, then decreased by 23.02% to $41.6 million in 2025, then rose by 29.36% to $53.9 million in 2026.
• The last three Cash & Equivalents figures came in at $53.9 million (Q2 2026), $37.8 million (Q1 2026), and $41.6 million (Q4 2025), per Business Quant data.